GENOVIS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37 SEK | +9.47% |
|
+24.58% | -28.85% |
| 15/05 | Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 14/03 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
Evolution of the average Target Price on Genovis AB
Price target over the last 5 years
History of analyst recommendation changes
9453934ada80d84fe41867213.eLAlCvFc5-dSQQPW7PM3hELSB3Fs31D-lUEGNCKgnQM.S9V9Q74s0q43JnOUv4IF5wSTMRIEkweS7BtjWVj17m0V5W9biWmNpmEOSg~389971423c88af0e6a7701bd52734edb
Analysts' Consensus
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
37
SEK
Average target price
51.5
SEK
Spread / Average Target
+39.19%
High Price Target
65
SEK
Spread / Highest target
+75.68%
Low Price Target
38
SEK
Spread / Lowest Target
+2.70%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
D+
EPS Revisions
- Stock Market
- Equities
- GENO Stock
- Consensus Genovis AB
